Royalty Pharma (RPRX) Short term Debt (2019 - 2026)
Royalty Pharma (RPRX) posted Short term Debt of $380.0 million for Q1 2026, little changed sequentially from $380.0 million in Q4 2025, and down 61.95% YoY from $998.6 million in Q1 2025.
Royalty Pharma (RPRX) Short term Debt (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Short term Debt for 8 years, with the latest figure at $380.0 million in Q1 2026.
- Quarterly Short term Debt fell 61.95% year-over-year to $380.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $380.0 million (down 61.95% YoY) and the FY2025 annual result came in at $380.0 million, down 61.92% from the prior year.
- Short term Debt was little changed at $380.0 million in Q1 2026 per RPRX's latest filing, from $380.0 million in the prior quarter.
- Over five years, Short term Debt peaked at $999.4 million in Q2 2025 and troughed at $116.0 million in Q2 2022.
- A 5-year average of $719.7 million and a median of $996.9 million in 2024 frame the typical range for Short term Debt.
- The sharpest annual moves came in 2022 and 2026: Short term Debt surged 824.19% in 2022, then sank 61.95% in 2026.
- Over 5 years, Short term Debt stood at $997.5 million in 2022, then advanced by 0.19% to $999.4 million in 2023, then fell by 0.16% to $997.8 million in 2024, then sank by 61.92% to $380.0 million in 2025, then changed by 0.0% to $380.0 million in 2026.
- According to Business Quant data, Short term Debt over the past three periods registered $380.0 million, $380.0 million, and $380.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 380.00 Mn |
| Mar 31, 2026 | 380.00 Mn |
| Dec 31, 2025 | 380.00 Mn |
| Sep 30, 2025 | 380.00 Mn |
| Jun 30, 2025 | 999.44 Mn |
| Mar 31, 2025 | 998.61 Mn |
| Dec 31, 2024 | 997.77 Mn |
| Sep 30, 2024 | 996.94 Mn |
| Jun 30, 2023 | 999.37 Mn |
| Mar 31, 2023 | 998.44 Mn |
| Dec 31, 2022 | 997.51 Mn |
| Sep 30, 2022 | 996.58 Mn |
| Jun 30, 2022 | 115.99 Mn |
| Mar 31, 2022 | 116.01 Mn |
| Dec 31, 2021 | 107.93 Mn |
| Sep 30, 2021 | 119.14 Mn |
| Jun 30, 2021 | 117.38 Mn |
| Mar 31, 2021 | 108.84 Mn |
| Dec 31, 2020 | 126.37 Mn |
| Jun 30, 2020 | 182.23 Mn |